Recognized Experts in ADME / DMPK / DDI by 98% of top pharma & countless others for drug metabolism and drug-drug interaction expertise.Learn More
This webinar was presented on Jan. 26, 2021 by Miki Fujishima, a manager in the Business Development Department at the...
In preclinical development, a drug will be evaluated for potential to cause a drug-drug interaction (DDI) using in vitro experiments and then calculations that...
The greatest strength of XenoTech is reputation for quality. That is an easy one. Attention to detail. Quality of reports. When it comes to DMPK...
Pharma Chief Development Officer
Great reports that are ready for submission to the Agency!
Pharma Senior Vice President of R&D
Every XenoTech employee I had contact with throughout these studies have been a pleasure to work with. The entire process was seamless. I never had...
Regulatory Affairs for Small Pharma
There is a lot of quality, skilled work that has gone into this data set. Compared to organizations that have done this type of work...
Great reports that are ready for submission to the Agency!Pharma Senior Vice President of R&D
Every XenoTech employee I had contact with throughout these studies have been a pleasure...Regulatory Affairs for Small Pharma
There is a lot of quality, skilled work that has gone into this data...ADME Consultant
Your drug’s journey…
Your drug’s journey…
Absorption, Distribution, Metabolism, and Excretion (ADME) properties of a xenobiotic describe its disposition and inform overall fate following administration. SEKISUI XenoTech serves 98% of top pharma and countless others by providing high-quality contracted ADME studies and test systems to precede or support clinical trials.
Drug Metabolism & Pharmacokinetics (DMPK) is a core discipline in drug discovery and development investigating how a drug is broken down and cleared, considering both ADME and DDI characteristics to evaluate and optimize properties of a new drug compound. Our drug metabolism and pharmacokinetics testing and products allows sponsors to understand properties of their compounds and to evaluate risk early in drug development and testing.
Drug-Drug Interaction (DDI) studies allow a drug developer to investigate the potential of a xenobiotic compound to interact with drug-metabolizing enzymes and drug transporters to predict the impact on the pharmacokinetics of the compound or coadministered drugs. Drug metabolism and drug transporter studies provide critical information in evaluating potential for drug-drug interactions and associated risks in preclinical drug development.
In Silico Modeling uses mathematical models to evaluate in vitro data in a way that provides meaningful risk prediction for drug metabolism and drug interaction issues later in development or clinical trials.
In Vitro Studies & Test Systems allow drug developers to use cell-based assays to determine ADME/PK characteristics and DDI potential of their drug compound.
Our In Vivo ADME / PK Studies use radiolabeled drug compound administered to laboratory animals to investigate an investigational compound’s pharmacokinetic propertiesinclusing drug metabolism and DDI risk.
Access ADME™ | Scientific Resources
Our new mini-webinar series exploring the what, why, and when of ADME, DMPK, and DDI within your drug’s development
Comparison Between the US FDA, EU EMA and Japan PMDA In Vitro DDI Guidance Documents: Are We Close to Harmonization?
Hear more about updates in regulatory expectations for drug metabolism and DDI data between FDA, EMA, and PMDA